Horoscopes Today, June 24, 2025
Here are the horoscopes for today, Tuesday, June 24, 2025.
For full daily and monthly horoscopes as well as expert readings, see our full Horoscopes experience.
What is your zodiac sign? A guide to what astrology can tell you about yourself
Get to know Cancer: Personality traits and more on this Zodiac sign
Cancer (June 22 - July 22)
Expand your presence! It's your time to take up space as the sun fuses with magnanimous Jupiter. Radiance suits you.
Read the full Cancer Daily Horoscope
Leo (July 23 - August 22)
You are prime for a spiritual breakthrough. The hidden parts of your soul speak while the sun aligns with Jupiter.
Read the full Leo Daily Horoscope
Virgo (August 23 - September 22)
Community is where your fortune is! Supportive social opportunities are plenty when the sun aligns with Jupiter. Grow your network.
Read the full Virgo Daily Horoscope
Libra (September 23 - October 22)
Possibilities for promotion? Soak up recognition as the sun joins Jupiter. You're in a golden moment for professional advancement.
Read the full Libra Daily Horoscope
Scorpio (October 23 - November 21)
Share your wisdom. What do you have to teach that others can benefit from? Feel confident in your intellectual authority.
Read the full Scorpio Daily Horoscope
Sagittarius (November 22 - December 21)
Ready to grow your portfolio? The sun meets Jupiter today, creating an ideal moment to explore big-picture investments.
Read the full Sagittarius Daily Horoscope
Capricorn (December 21 - January 19)
Optimistic about joining forces? Partnership is the secret sauce for advancement as the sun joins Jupiter. Pair up with confidence.
Read the full Capricorn Daily Horoscope
Aquarius (January 20 - February 18)
Take your daily rituals to new heights. What would soulful self-care look like for you? Focus on the feeling first.
Read the full Aquarius Daily Horoscope
Pisces (February 19 - March 20)
Embrace the freedom of self-expression! Today, the sun meets Jupiter, encouraging you to playfully live in the moment.
Read the full Pisces Daily Horoscope
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
an hour ago
- Miami Herald
Patrick McNamara Named Chief Commercial Officer at Yunu, Driving Growth in Trial Imaging for Pharma
CARY, NC / ACCESS Newswire / June 24, 2025 / Yunu, the creator and leader in cloud-native imaging workflows for clinical trials, proudly announces Patrick McNamara as its new Chief Commercial Officer. With over two decades of experience in clinical research and business development, McNamara has played a pivotal role in Yunu's rapid expansion across the pharmaceutical, biotech, and contract research organization (CRO) sectors. McNamara's appointment reinforces Yunu's commitment to advancing transformative clinical trial imaging solutions at scale. His deep industry knowledge is built upon years of hands-on leadership as the prior VP of Business Development for the clinical endpoint division of a major CRO as well as key oversight of commercial and operational teams. His extensive experience and strategic vision accelerate Yunu's ability to deeply engage with sponsors and CROs in Yunu's industry-wide effort to transform trialimaging workflows, accelerate new therapies, and improve data quality. "We are thrilled to appoint Patrick McNamara as our Chief Commercial Officer," said Jeff Sorenson, CEO & Co-founder of Yunu. "Patrick's unique perspective allows Yunu to orient our teams around the specific needs and processes of pharma while also fine-tuning our go-to-market as we continue to deliver game-changing trial acceleration and transparency." Yunu recently unveiled a groundbreaking software release that empowers pharma sponsors to rapidly configure new studies, connect to readers, and ensure real time access to their imaging data within their primary data systems. This advancement underscores Yunu's role as an innovator and leader in harmonizing multi-site trials, reducing complexity, and accelerating trial imaging timelines. Yunu is also managing all imaging endpoints delivered to sponsors at more than 25% of NCI-designated Comprehensive Cancer Centers. The platform's impact will be discussed during a special session with City of Hope leadership in addition to showcasing these latest advancements during the 17th Annual AACI CRI Meeting in Chicago from Monday, June 23rd, to Wednesday, June 25th. ABOUT YUNUYunu enables life sciences organizations to streamline imaging workflows, improve accuracy, and accelerate timelines. Yunu's platform supports clinical trials across various therapeutic areas, offering scalability and flexibility for organizations of all sizes. For more information, visit and follow us on LinkedIn or X @Yunu_Inc.
Yahoo
3 hours ago
- Yahoo
KIF18A Inhibitor Clinical Trials FDA Approved KIF18A Targeting Therapies Market Report
KIF18A Therapy Commercial Launch Expected By 2030 Says Kuick Research in New Research Study Delhi, June 24, 2025 (GLOBE NEWSWIRE) -- Global KIF18A Targeting Therapies Market Trends, Clinical Trials, Technology Platforms & Future Outlook 2025 Report Highlights & Findings: First KIF18A Targeting Therapy Commercial Availability Expected By 2030 Highest Phase Of Development: Phase-I/II KIF18A Targeting Therapies In Clinical Trials: > 10 Therapies KIF18A Targeting Therapies Clinical Trials Insight By Company, Country, Indication & Phase KIF18A Targeting Therapies Market Development Trends Insight KIF18A Therapies Technology Platforms Insight Download Report: The global oncology landscape is witnessing rapid progress in precision medicine, and one of the most lead nominees in emerging targets is Kinesin Family Member 18A (KIF18A). It is a mitotic motor protein that is essential for chromosome alignment during mitosis, which facilitates proper segregation of chromosomes. Its perturbation leads to genomic instability, which is a distinguishing feature of cancer. Extrapolations of KIF18A have also been seen in various cancers such as ovarian and breast cancer, with an association with prognosis, drug resistance, and the potential to metastasize. As a crucial protein involved in mitosis and overexpression in cancer, KIF18A is now a promising therapeutic target. Targeting KIF18A interferes with mitotic mechanisms in chromosomally unstable (CIN-positive) cancer cells, causing selective death of cancer cells. In contrast to conventional chemotherapies, which indiscriminately impact all proliferating cells, KIF18A inhibitors provide a more selective and less toxic option by taking advantage of cancer cells' vulnerability to proper mitosis. The major approach is small molecule inhibitors that disrupt KIF18A's motor activity, hindering it from modulating microtubule dynamics at the kinetochore. It leads to mitotic arrest and failure of chromosome alignment, ultimately triggering apoptosis in cancer cells. Clinical development is progressing well. Volastra Therapeutics, a forerunner in this arena, is developing two KIF18A-targeting molecules: Sovilnesib (AMG650), acquired from Amgen and underway in Phase I trials for platinum-resistant high-grade serous ovarian cancer, and VLS-1488, an in-house oral inhibitor in Phase I/II. Both molecules displayed favorable safety profiles and early anti-tumor effects, with particular efficacy in high-chromosomal-instability tumors. Volastra's pipeline demonstrates the therapeutic potential of inhibiting KIF18A to treat difficult-to-treat cancers. Accent Therapeutics is also advancing with ATX-295, an oral KIF18A inhibitor in initial clinical testing for solid tumors such as triple-negative breast and high-grade serous ovarian cancers. Their biomarker strategy makes use of genomic instability markers such as whole-genome doubling to better optimize patient selection and optimize therapy outcomes. AI based drug discovery is providing additional impetus to this area. Insilico Medicine has utilized proprietary platforms such as Chemistry42 and PandaOmics to discover ISM9682, a new macrocyclic KIF18A inhibitor with high preclinical efficacy. The AI platforms facilitate rapid optimization of candidates with increased specificity and pharmacological profiles, highlighting the growing use of sophisticated computational approaches in drug discovery. Aside from clinical advancement, the market opportunity for KIF18A inhibitors is also robust. As precision oncology gains more attention, the therapies are well poised to capture the opportunity of targeted therapies, particularly in diseases that are refractory to current treatments. Various companies, including Nvidia-funded Iambic Therapeutics, Aurigene Oncology, Simcere Zaiming Pharmaceutical, and Amgen, are developing promising product candidates in preclinical phases. Overall, the KIF18A-targeted therapy market is changing very quickly, powered by strong scientific justification, initial clinical success, and novel development approaches. As additional preclinical and clinical information becomes available, the market has significant potential for strong growth, powered by partnerships, application of artificial intelligence and machine learning tactics, and the overall dedication to creating targeted and individualized cancer therapeutics. CONTACT: Neeraj Chawla Research Head Kuick Research neeraj@ in to access your portfolio
Yahoo
4 hours ago
- Yahoo
Natera Gains Medicare Coverage for WGS Signatera, Leerink Reaffirms Price Target
Natera Inc. (NASDAQ:NTRA) is one of billionaire Stan Druckenmiller's top stock picks with huge upside potential. Leerink Partners analysts reiterated their Outperform rating on Natera Inc. (NASDAQ:NTRA) on June 4. Given recent adjustments to Medicare's reimbursement of Natera's WGS Signatera assay, the analysts maintained their price target for the company at $220. Natera Inc. (NASDAQ:NTRA) recently revealed that MolDX had approved Medicare coverage for its WGS Signatera assay. The update followed the findings of a bridging study that showed similar performance between the WGS Signatera and the previously released WES Signatera. The WGS Signatera assay has been expanded to encompass a number of ailments, including colorectal cancer, breast cancer, bladder cancer, and pan-cancer immunotherapy monitoring. Analysts expect that WES Signatera will continue to dominate Signatera volumes in the near term, despite the recent coverage. That said, now that it is eligible for reimbursement, the WGS Signatera assay may see a modest rise in usage. One of the top providers of cell-free DNA and genetic testing, Natera Inc. (NASDAQ:NTRA) focuses primarily on women's health, cancer, and organ health. While we acknowledge the potential of NTRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
